Find Expert Doctors on Mucopolysaccharidosis II311 top medical experts on Mucopolysaccharidosis II across 42 countries and 24 U.S. states, including 133 MDs (Physicians). This is based on an objective analysis of their Scientific Publications, Clinical Trials, Medicare, and NIH Grants.
- Mucopolysaccharidosis II: Systemic lysosomal storage disease marked by progressive physical deterioration and caused by a deficiency of L-sulfoiduronate sulfatase. This disease differs from mucopolysaccharidosis I by slower progression, lack of corneal clouding, and X-linked rather than autosomal recessive inheritance. The mild form produces near-normal intelligence and life span. The severe form usually causes death by age 15.
- Clinical guidelines are the recommended starting point to understand initial steps and current protocols in any disease or procedure:
- Broader Categories (#Experts): Mucopolysaccharidoses (1,530), X-Linked Mental Retardation (2,803).
- Clinical Trials
: at least 58 including 7 Active, 26 Completed, 15 Recruiting - Synonyms: Hunter Syndrome Gargoylism, Hunter's Syndrome, Iduronate 2-Sulfatase Deficiency, Iduronate Sulfatase Deficiency, Sulfoiduronate Sulfatase Deficiency
- Muenzer, Joseph Pediatrics
Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Top HospitalDisclosed payments in 2021 from 6 biomedical companies, totalling $14,286, including $8,826 from Takeda Pharmaceuticals U.S.A., Inc.Subjects: Iduronate Sulfatase; Enzyme Replacement Therapy; Brain; Cognition Disorders; LungCategories: Drug Therapy; Administration & Dosage; Methods; Pathology; Physiopathology; Therapeutic Use - Harmatz, Paul R Pediatric Gastroenterology UCSF Benioff Childrens Hospital Oakland, Oakland, California.Disclosed payments from biomedical company (Chiesi USA, Inc.) in 2021 for $10,200Subjects: Iduronate Sulfatase; Enzyme Replacement Therapy; Biological Variation, Individual; Cognition; Data CollectionCategories: Drug Therapy; Epidemiology; Diagnosis; Genetics; Statistics & Numerical Data; Therapeutic Use
- Whitley, Chester B Pediatrics Gene Therapy Center, Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA. Top HospitalDisclosed payments from biomedical company (GENZYME CORPORATION) in 2021 for $2,165Subjects: Mucopolysaccharidosis I; Iduronate Sulfatase; Mucopolysaccharidosis VI; Antibodies, Neutralizing; Body CompositionCategories: Physiopathology; Metabolism; Drug Effects; Drug Therapy; Genetics; Immunology
- Orchard, Paul J Pediatric Hematology-Oncology Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA. Top HospitalPhysician Highly PublishedDisclosed payments from biomedical company (GENZYME CORPORATION) in 2021 for $1,743Subjects: Mucopolysaccharidosis I; Mucopolysaccharidosis VI; Body Composition; Body Height; Bone DensityCategories: Physiopathology; Drug Effects; Metabolism; Pathology; Complications; Drug Therapy
- Wang, Raymond Y Pediatrics Department of Pediatrics, University of California-Irvine School of Medicine, Orange, CA 92868, USA. .PhysicianDisclosed payments in 2021 from 3 biomedical companies, totalling $5,850, including $2,400 from Takeda Pharmaceuticals U.S.A., Inc.Subjects: Mucopolysaccharidosis I; Aortic Diseases; Carotid Arteries; Coronary Artery Disease; Dilatation, PathologicCategories: Pathology; Diagnosis
- Burton, Barbara K Psychiatry Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, IL; Northwestern University Feinberg School of Medicine, Chicago, IL. Electronic address: . Top HospitalSubjects: Iduronate Sulfatase; Enzyme Replacement Therapy; Data Collection; Iduronic Acid; Neonatal ScreeningCategories: Therapeutic Use; Drug Therapy; Diagnosis; Adverse Effects; Methods; Physiopathology
- Whiteman, David A H Forensic Pathology Research & Development, Shire Human Genetic Therapies, Inc., Lexington, MA, USA.Subjects: Iduronate Sulfatase; Enzyme Replacement Therapy; Quality of Life; Surveys and Questionnaires; AntibodiesCategories: Drug Therapy; Therapeutic Use; Adverse Effects; Immunology; Methods; Psychology
- Lund, Troy C Pediatric Hematology-Oncology Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA. Top HospitalPhysicianDisclosed payments in 2021 from 3 biomedical companies, totalling $9,736.5, including $7,336.5 from SANOFI US SERVICES INC.Subjects: Mucopolysaccharidosis I; Corneal Diseases; Epidermal Cells; Mucopolysaccharidosis VI; Muscle, SkeletalCategories: Physiopathology; Pathology; Complications
- Nguyen, Hoang N Anesthesiology Denali Therapeutics Inc., South San Francisco, California, USA.PhysicianMedical school: Virginia Commonwealth University, School of Medicine (MD, 1990)Medicare AcceptedSubjects: Iduronate Sulfatase; Blood-Brain Barrier; Brain; Enzyme Replacement Therapy; GlycosaminoglycansCategories: Metabolism; Administration & Dosage; Blood; Cerebrospinal Fluid; Drug Therapy; Methods
- Steinberger, Julia Pediatric Cardiology Division of Pediatric Cardiology, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN, USA. Top HospitalPhysicianDisclosed payments from biomedical company (SANOFI-AVENTIS U.S. LLC) in 2021 for $1,329Subjects: Mucopolysaccharidosis I; Carotid Arteries; Coronary Artery Disease; Mucopolysaccharidosis VI; Muscle, SkeletalCategories: Pathology; Physiopathology
- Polgreen, Lynda E Pediatric Endocrinology Division of Pediatric Endocrinology, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN, USA. Top HospitalPhysician Highly PublishedDisclosed payments in 2021 from 7 biomedical companies, totalling $17,305.57, including $13,033.57 from BioMarin Pharmaceutical Inc.Subjects: Mucopolysaccharidosis I; Mucopolysaccharidosis VI; Body Composition; Body Height; Bone DensityCategories: Pathology; Physiopathology; Drug Effects; Metabolism; Drug Therapy; Physiology
- Mason, Robert W Ophthalmology Nemours/Alfred I. duPont Hospital for Children, Wilmington, DE, United States; Department of Biological Sciences, University of Delaware, Newark, DE, United States.Physician Highly PublishedMedical school: Columbia University College of Physicians and Surgeons (MD, 1996)Medicare AcceptedDisclosed payments in 2021 from 4 biomedical companies, totalling $71.98, including $34.48 from Genentech USA, Inc.Subjects: Hematopoietic Stem Cell Transplantation; Enzyme Replacement Therapy; Activities of Daily Living; Disease Management; Practice Guidelines as TopicCategories: Therapy; Methods
- Fan, Zheng Pediatrics Department of Neurology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. Top HospitalPhysician Clinical TrialMedical school: Other (MD, 1991)Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 76/100Subjects: Brain; Cognition Disorders; Iduronate Sulfatase; Magnetic Resonance ImagingCategories: Pathology; Administration & Dosage; Drug Therapy; Methods
- Giugliani, Roberto Department of Genetics, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre 90040-060, Brazil.Subjects: Iduronate Sulfatase; Enzyme Replacement Therapy; Glycosaminoglycans; DNA Damage; Mucopolysaccharidosis IVCategories: Genetics; Methods; Drug Therapy; Metabolism; Therapeutic Use; Administration & Dosage
- Scarpa, Maurizio Department of Womens and Childrens Health, University of Padova, 35128 Padova, Italy. .Subjects: Iduronate Sulfatase; Brain; Enzyme Replacement Therapy; Neuroglia; Bone Diseases, DevelopmentalCategories: Drug Therapy; Metabolism; Pathology; Therapeutic Use; Diagnostic Imaging; Drug Effects
- Sonoda, Hiroyuki JCR Pharmaceuticals, Hyogo 659-0021, Japan.Subjects: Iduronate Sulfatase; Receptors, Transferrin; Recombinant Fusion Proteins; Antibodies, Monoclonal; Blood-Brain BarrierCategories: Administration & Dosage; Drug Therapy; Metabolism; Antagonists & Inhibitors; Therapeutic Use; Drug Effects
- Gelb, Michael H Psychiatry Department of Chemistry, University of Washington, Seattle, WA; Department of Biochemistry, University of Washington, Seattle, WA. Top HospitalPhysicianRelevant US NIH Grant Funding: $582,226 over the last 5 yearsMedical school: Other (MD, 1998)Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 84.8/100Subjects: Neonatal Screening; Tandem Mass Spectrometry; Lysosomes; Mucopolysaccharidosis I; Mucopolysaccharidosis IVCategories: Diagnosis; Methods; Blood; Enzymology
- Okuyama, Torayuki Center for Lysosomal Storage Diseases, National Centre for Child Health and Development, Tokyo 157-8535, Japan.Subjects: Iduronate Sulfatase; Glycoproteins; Enzyme Replacement Therapy; Mutation; Receptors, TransferrinCategories: Genetics; Therapeutic Use; Drug Therapy; Pathology; Antagonists & Inhibitors; Therapy
- Amato, David A Internal Medicine Shire, 300 Shire Way, Lexington, MA, 02421, USA. .Physician Clinical TrialSubjects: Iduronate Sulfatase; Antibodies; Enzyme Replacement TherapyCategories: Immunology; Drug Therapy; Therapeutic Use; Adverse Effects
These expert listings are
for individual use without a fee. Biotechs,
Pharmaceuticals, Recruiters, Consultants, Investors, Law firms, and
other organizations may use this only for quick evaluations (no downloads, screen scraping or using the data) to identify the top medical experts for recruiting, advisory panels, boards,
and consulting. Please contact
us for licensing, customized queries, feedback and questions.
Note:
- These experts have limited publications on this topic in our database, so expertise assessment may not be accurate.
- Only the top 20 experts are shown. You may filter your results or use the geolocation tabs. Contact us to purchase the entire list.